Summary of Conference Call Notes Industry or Company Involved - The discussion primarily revolves around the pharmaceutical industry, particularly focusing on the implications of U.S. drug pricing policies and U.S.-China trade negotiations on Chinese pharmaceutical companies and their market opportunities. Core Points and Arguments 1. **Positive Impact of U.S.-China Negotiations on Pharmaceuticals** The recent U.S.-China negotiations are viewed as a significant positive for the pharmaceutical sector, alleviating previous concerns regarding trade impacts on drug pricing and exports of innovative drugs and raw materials [1] 2. **U.S. Drug Pricing Policy Changes** Trump's announcement of an executive order to reduce prescription drug prices by 30% to 80% is highlighted. The U.S. drug pricing system, characterized by high list prices, is under scrutiny, with the potential for significant price reductions impacting the market [2][3] 3. **Global Drug Pricing Context** U.S. drug prices are noted to be among the highest globally, particularly for innovative drugs, which are approximately 300% higher than prices in countries like Japan and Germany. This pricing structure encourages innovation but also raises concerns about affordability [3] 4. **Encouragement of Competition** The U.S. policy aims to accelerate competition among high-priced drugs, encouraging the entry of biosimilars and generic drugs, which could benefit Chinese pharmaceutical companies that can offer lower-cost alternatives [4][6] 5. **Opportunities for Chinese Pharmaceutical Companies** The reduction in U.S. drug prices is expected to create opportunities for Chinese companies, particularly in the fast-follow and biosimilar segments, as they can provide high-quality, cost-effective alternatives [6][8] 6. **Long-term Trends Favoring Chinese Innovation** The inefficiencies in innovation among multinational pharmaceutical companies may lead to increased reliance on Chinese innovation and manufacturing capabilities, especially if U.S. companies face cost pressures [7][8] 7. **Market Dynamics and Export Opportunities** The easing of trade tensions is anticipated to enhance the macroeconomic environment in China, leading to improved domestic demand and potential export opportunities for medical devices and raw materials [10][9] 8. **Impact of Drug Price Reductions on Market Dynamics** The anticipated drug price reductions in the U.S. are not expected to significantly diminish the addressable market for Chinese companies, as their market share in the U.S. remains relatively small [11][12] 9. **Long-term Supply Chain Considerations** U.S. concerns regarding supply chain security may lead to a push for domestic manufacturing, which could have long-term implications for Chinese companies seeking to penetrate the U.S. market [14][15] 10. **Investment Recommendations** The call suggests focusing on three categories of companies: innovative leaders, those with strong business development (BD) expectations, and upstream suppliers with global advantages, as the market enters a new growth cycle [16][18] Other Important but Possibly Overlooked Content 1. **Sector-Specific Insights** The discussion includes insights into specific companies and their competitive advantages, such as the potential for certain drugs to achieve significant market penetration despite pricing pressures [31][33] 2. **Emerging Trends in Medical Devices** The call also touches on the medical device sector, emphasizing the importance of high-end equipment and the potential for growth in home healthcare products, which may offer higher profit margins compared to domestic markets [25][26] 3. **Long-term Growth Projections** There is an optimistic outlook for the pharmaceutical sector, with expectations of a gradual recovery in demand and performance improvements in the coming years, driven by policy support and market dynamics [29][40] 4. **Focus on Innovation and R&D** The emphasis on innovation and the need for companies to adapt to changing market conditions is reiterated, highlighting the importance of R&D in maintaining competitive advantages [19][20] 5. **Market Sentiment and Future Outlook** The overall sentiment is cautiously optimistic, with a belief that the current market conditions present opportunities for growth and investment in the pharmaceutical and medical device sectors [46][47]

Market Overview - The Shanghai Composite Index is at 3500.42 points, slightly down by 0.13%, with a total trading volume of 674.96 billion yuan [1] - As of now, 50 A-shares have surpassed their annual line, indicating a positive market sentiment [1] Notable Stocks - The stocks with the highest deviation rates above the annual line include: - Furui Co., Ltd. (300049) with a deviation rate of 5.83% and a daily increase of 7.83% [1] - Haide Co., Ltd. (000567) with a deviation rate of 4.84% and a daily increase of 7.77% [1] - Tianye Co., Ltd. (832023) with a deviation rate of 3.71% and a daily increase of 6.35% [1] - Other stocks that have just crossed the annual line with smaller deviation rates include: - Wansheng Co., Ltd. (002739) with a deviation rate of 2.70% and a daily increase of 3.02% [1] - ST Guandian (688287) with a deviation rate of 2.14% and a daily increase of 2.67% [1] Trading Activity - The trading turnover rate for notable stocks varies, with Furui Co., Ltd. at 4.06% and Haide Co., Ltd. at 2.59% [1] - The latest prices for these stocks are as follows: - Furui Co., Ltd. at 39.40 yuan [1] - Haide Co., Ltd. at 6.52 yuan [1] - Tianye Co., Ltd. at 4.69 yuan [1]

Core Viewpoint - The chain pharmacy industry in China is facing significant challenges, including declining profits, difficulties in online transformation, and a lack of investor confidence, leading to a period of deep adjustment and potential consolidation [1][8][16]. Group 1: Industry Performance - In 2024, only Yifeng Pharmacy among the six major listed chain pharmacy brands achieved profit growth, while the other five experienced varying degrees of profit decline [1][5]. - The revenue growth of the six major chains did not exceed 10% in 2024, with the highest growth at 8.01%, a stark contrast to previous years where growth often exceeded 10% [5][6]. - Yifeng Pharmacy was the only company to report profit growth, while others, including Shuyupingmin, faced their first losses since 2019 [6][7]. Group 2: Market Dynamics - The number of offline pharmacies in China grew from 520,000 in 2019 to 700,000 in 2024, with major chains aggressively expanding through various methods [2]. - The expectation of prescription outflow has not materialized, with prescriptions returning to grassroots medical institutions instead of flowing to retail pharmacies [3][4]. - The introduction of stricter regulations, such as comprehensive inspections of pharmacies and mandatory traceability codes, has increased compliance costs for pharmacies [4]. Group 3: Investor Sentiment - There have been multiple instances of major shareholders in chain pharmacies, such as Yifeng and Laobaixing, reducing their stakes, raising concerns about the industry's future [7]. - Several chain pharmacies are reportedly seeking to sell their businesses, but a lack of interested buyers indicates a significant loss of confidence in the industry [1][6]. Group 4: Online Transition - The online pharmacy market is growing, with online sales reaching 329.2 billion yuan in 2024, while physical pharmacy sales declined for the first time [10]. - Major online pharmacy players like JD Health and Alibaba Health reported strong revenue growth, contrasting with the struggles of traditional pharmacies [10][11]. - Chain pharmacies are increasingly investing in online channels, with significant growth in their O2O (Online to Offline) sales, although they face challenges in competing with larger platforms [11][12]. Group 5: Strategic Shifts - Chain pharmacies are exploring non-pharmaceutical business models, with companies like Yixin Tang and Laobaixing diversifying their product offerings to include health and personal care items [14][15]. - The shift towards a more diversified product range aims to reduce reliance on prescription sales and adapt to changing consumer preferences [14][16]. - The industry is undergoing a transformation phase, necessitating a reevaluation of value propositions in light of declining prescription flows and increased competition from e-commerce [16][17].

Summary of Key Points Core Viewpoint The announcements from Yifeng Pharmacy Chain Co., Ltd. detail the status of its convertible bonds and the management of idle raised funds through financial products, indicating a strategic approach to enhance financial efficiency and shareholder returns. Group 1: Convertible Bond Conversion Status - As of June 30, 2025, a total face value of 163,000 yuan of "Yifeng Convertible Bonds" has been converted into 4,950 shares of the company's A-shares, representing 0.0004% of the total shares before conversion [2][4]. - The remaining unconverted "Yifeng Convertible Bonds" have a face value of 1,797,269,000 yuan, accounting for 99.9909% of the total issuance [2][4]. - During the quarter from April 1, 2025, to June 30, 2025, 2,000 yuan of "Yifeng Convertible Bonds" were converted into 60 shares [2][4]. Group 2: Convertible Bond Issuance Overview - The company issued 17,974,320 convertible bonds with a total face value of 179,743.20 million yuan, approved by the China Securities Regulatory Commission on March 4, 2024 [3]. - The bonds were listed on the Shanghai Stock Exchange on March 27, 2024, and can be converted into shares starting from September 9, 2024 [3]. Group 3: Management of Idle Funds - The company redeemed structured deposits totaling 10,300.00 million yuan and plans to continue investing 11,400.00 million yuan in new financial products [6][8]. - The board approved the use of up to 30,000.00 million yuan of idle raised funds for financial investments, ensuring that it does not affect the normal operation of investment projects [6][10]. - The investment strategy aims to enhance the efficiency of idle funds and increase company returns without impacting daily operations [13].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-062 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 累计转股情况：截至 2025 年 6 月 30 日，累计已有面值 163,000 元"益丰转 债"转为公司 A 股普通股，累计转股股数为 4,950 股，占"益丰转债"转股前 公司已发行普通股股份总额的 0.0004%。 未转股可转债情况：截至 2025 年 6 月 30 日，尚未转股的"益丰转债"面值 为人民币 1,797,269,000 元，占"益丰转债"发行总量的比例为 99.9909%。 本季度转股情况："益丰转债"自 2024 年 9 月 9 日起可转换为公司股份，2025 年 4 月 1 日至 2025 年 6 月 30 日共有面值 2,000 元"益丰转债"转为公司 A 股 普通股，转换为股份数 60 股。 一、可 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-063 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次赎回产品名称：智汇系列进取型看涨三层区间 59 天结构性存款 （1,000.00 万），智汇系列进取型看涨三层区间 91 天结构性存款（4,000.00 万）， 共赢智信利率挂钩人民币结构性存款 A07652 期（6,400.00 万）。 赎回金额：10,300.00 万元 本次继续委托理财金额：11,400.00 万元 已履行的审议程序：经公司第五届董事会第十五次会议审议通过，同意在 确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情况下，使 用最高额度不超过 30,000.00 万元募集资金进行委托理财，用于购买安全性高、 流动性好的理财产品，自董事会审议通过起 12 ...

Core Viewpoint - The retail pharmacy industry is experiencing accelerated closures, with a total of 39,228 stores shut down in 2024, leading to a potential recovery in customer traffic and profit margins for leading pharmacies post-industry consolidation [1][2]. Group 1: Industry Trends - The number of closed pharmacies in 2024 is reported as follows: Q1 - 6,778, Q2 - 8,791, Q3 - 9,545, Q4 - 11,414, indicating a significant acceleration in closures, with a net decrease of 3,395 stores in Q4 alone [1]. - The industry is facing a severe environment for small and medium-sized pharmacies due to weak consumer power, medical insurance cost control, and enhanced regulatory measures, leading to a consolidation trend [1]. Group 2: Market Opportunities - Leading retail pharmacies are expected to benefit from a "siphon effect" in customer traffic due to their first-mover advantage in local market outpatient coordination, which may enhance customer spending and overall performance [2]. - The implementation of outpatient coordination policies is anticipated to increase medical insurance spending and related product consumption, potentially raising average transaction values [2]. Group 3: Strategic Initiatives - Leading pharmacies are actively exploring diversified operations and innovative store management to enhance market competitiveness, such as transforming into service complexes and creating new store formats [3]. - Examples include Yifeng Pharmacy's transition towards service complexes and Yixin Hall's development of new store formats to attract more customers [3]. Group 4: Recommended Stocks - Companies that are expected to benefit from the industry cycle and demonstrate superior management capabilities include Yifeng Pharmacy (603939.SH) and Daclin (603233.SH) as recommended stocks, while beneficiaries include Laobaixing (603883.SH), Yixin Hall (002727.SZ), and Jianzhijia (605266.SH) [4].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-061 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●被担保人名称：江苏益丰大药房连锁有限公司（以下简称"江苏益丰"） 为益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）合并报表 范围内子公司。 ●本次担保金额及累计担保余额：本次公司为子公司江苏益丰提供担保金额 30,000.00 万元。截止本公告披露日，公司实际为其提供的担保余额为 40,000.00 万元（含本次担保）。 ●本次担保是否有反担保：无 ●对外担保的逾期累计数量：无 一、担保情况概述 1、担保基本情况及履行决策程序 公司于 2025 年 4 月 28 日召开的第五届董事会第十六次会议《关于为子公司 申请银行授信提供担保的议案》，同意公司为子公司江苏益丰提供总额不超过 309,000.00 ...

债券简称：益丰转债 债券代码：113682 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 发行人 中信证券股份有限公司关于 益丰大药房连锁股份有限公司 Yifeng Pharmacy Chain Co., Ltd. （湖南省常德市武陵区白马湖街道富强社区人民路 2638 号） 债券受托管理人 中信证券股份有限公司 益丰大药房连锁股份有限公司 （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 2025 年 6 月 1 重要声明 本报告依据《可转换公司债券管理办法》《公司债券发行与交易管理办法》 （以下简称《管理办法》）、《公司债券受托管理人执业行为准则》（以下简称 《执业行为准则》）等相关规定，及《益丰大药房连锁股份有限公司公开发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）《益丰大药房连锁 股份有限公司 2024 年年度报告》等相关信息披露文件、益丰大药房连锁股份有 限公司（以下简称"益丰药房"，"发行人"或"公司"）出具的相关文件以及 提供的相关资料或第三方中介机构出具的专业意见等，由本期公司债券受托管理 人中信证券股份有限公司（以下简称"中信证券"）编制 ...

Core Viewpoint - The credit rating for Yifeng Pharmacy's convertible bonds remains stable at "AA," with no changes from the previous rating [1]. Group 1 - The previous rating for the convertible bonds was "AA," and the issuer's rating was also "AA," with a stable outlook [1]. - The current rating results for both the issuer and the convertible bonds are unchanged from the last assessment [1]. - The credit rating agency, United Credit Ratings Co., conducted a comprehensive analysis of the company's operational status and industry conditions for this tracking rating [1]. Group 2 - The tracking credit rating report for the convertible bonds can be found on the Shanghai Stock Exchange website [2]. - The announcement is made by the board of directors of Yifeng Pharmacy [3].